ALT Profile
Altimmune Inc. (ALT) is a clinical-stage biopharmaceutical company that focuses on developing immunotherapeutic products for treating cancer and infectious diseases. The company's pipeline includes several drug candidates based on its proprietary technologies, such as T-cell activation and immune modulation.
One of the company's lead drug candidates is AdCOVID, a single-dose intranasal vaccine for preventing COVID-19. AdCOVID is designed to trigger an immune response against the SARS-CoV-2 virus and is being developed in collaboration with the University of Alabama at Birmingham. Altimmune is also developing other vaccine candidates for treating hepatitis B, anthrax, and influenza.
In addition to its vaccine programs, Altimmune is developing drug candidates for treating various types of cancer, including pancreatic cancer and non-small cell lung cancer. The company's pipeline also includes a drug candidate for treating NASH, a type of liver disease.
Altimmune's approach to drug development involves leveraging its proprietary technologies to develop immunotherapeutic products that can activate and modulate the immune system to treat various diseases. The company is headquartered in Gaithersburg, Maryland, and was founded in 1997.
|
